FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Pfizer Reports Favorable Trial Data on Arthritis Drug

[ Price : $8.95]

Pfizer says a recent Phase 3 study with tasocitinib in rheumatoid arthritis patients met two primary endpoints.

Genetic Testing Outreach Program Boosts Use

[ Price : $8.95]

Medco Research Institute says a pharmacy-based outreach program boosts consent for and participation in genetic testing to improve...

FDA Approves BMS Diabetes Combo Drug

[ Price : $8.95]

FDA approves a Bristol-Myers Squibb NDA for Kombiglyze XR (saxagliptin and metformin extended-release) for treating Type 2 diabete...

FDA Not Considering Drug Model for Devices

[ Price : $8.95]

In its efforts to harmonize data standards for regulatory purposes, FDA principal deputy commissioner Joshua Sharfstein denies the...

FDA OKs Lilly's Cymbalta for Musculoskeletal Pain

[ Price : $8.95]

FDA approves Eli Lillys Cymbalta (duloxetine HCl) for managing chronic musculoskeletal pain.

FDA Approval Letter for Mammography System

[ Price : $8.95]

FDA sends Carestream Health an approval letter for its CareStream DirectView CR, a high-resolution computed radiography system for...

FDA Reclassifies Full-Field Digital Mammography to Class 2

[ Price : $8.95]

Federal Register Final rule: FDA reclassifies the full-field digital mammography system from Class 3 to Class 2 with a guidance do...

Special Controls Guidance on Mammography Systems

[ Price : $8.95]

Federal Register Notice: FDA releases a special controls guidance on full-field digital mammography system.

MannKind Says Afrezza Whistleblower Suit Has No Merit

[ Price : $8.95]

MannKind says it will vigorously defend a suit charging that it fired a regulatory affairs senior manager in retaliation for his c...

Advisors Support Pozen Phase 3 Trial Design

[ Price : $8.95]

Pozen says a Gastrointestinal Drugs Advisory Committee vote supports its Phase 3 trial design for PA 32540 for secondary preventio...